 |
| Global Peptide Therapeutics Market Size |
Peptide therapeutics are small protein-like molecules which are used to
modulate biological processes. They offer several advantages over small
molecule drugs including high target specificity, low toxicity, and ability to
address diseases which are difficult to treat with conventional drugs.
The global peptide therapeutics market is estimated to
be valued at US$ 51133.71 Bn in 2024 and is expected to exhibit a CAGR of 8.9% over the forecast period
of 2024 to 2030.
Key players operating in the peptide therapeutics are IBM Corporation, SAP SE,
Oracle Corporation, ABB Ltd., Infor, Inc., Ultimo Software Solutions BV, CARL
International SA, eMaint Enterprises, LLC, Mainsaver, Inc., MEX Pty Ltd., Asset
Works LLC, and CGI, Inc. Peptide therapeutics offer several advantages over
conventional small molecule drugs such as high target specificity, low
toxicity, and ability to modulate the immune system making them promising
candidates for developing targeted therapies. The global expansion of key
players in the peptide therapeutics market through partnerships, mergers, and
acquisitions is expected to supplement research and development activities and
help improve access to novel peptide-based drugs across various regions.
Market Drivers
Rising prevalence of chronic diseases globally is one of the key factors
augmenting the growth of Global
Peptide Therapeutics Market Size. Peptide based drugs have potential
applications in conditions ranging from cancer, diabetes to neurodegenerative
disorders where currently only temporary symptomatic relief can be offered.
Furthermore, increasing adoption of targeted drug therapies along with faster
development and approval of novel peptide drugs will propel the market growth
over the forecast period.
Market Restraints
High research and development costs associated with development of peptide
drugs is one of the major challenges faced by players operating in this market.
Peptides have low oral bioavailability which necessitates alternative delivery
methods like injections further adding to the cost of therapy. Stringent
regulatory guidelines for approval of novel peptide therapeutics also act as a
market restrain.
Segment Analysis
The cancer peptide therapeutics segment dominates the market. Peptide
therapeutics are effective in delivering targeted cancer therapies and has
shown promising results in treating various cancers. They provide greater
selectivity than small molecule drugs and are excellent targeting agents.
Hence, cancer peptide therapeutics offer customized treatment options and have
minimal side effects, making it the dominant sub-segment.
Global Analysis
North America dominates the peptide therapeutics market due to high acceptance
of therapeutic peptides, presence of major players, and developed healthcare
infrastructure. The growth in this region is attributed to the rising
prevalence of chronic diseases, growing R&D expenditure by pharmaceutical
companies, and introduction of novel peptide-based drugs. Asia Pacific is
expected to witness the highest growth during the forecast period owing to
increasing healthcare expenditure, large population base susceptible to chronic
diseases, and rising focus of international players in this region.
Get More Insights On This Topic: https://www.newsstatix.com/the-global-peptide-therapeutics-market-is-estimated-to-driven-by-growing-demand-for-personalized-medicine/